Breaking
•Breaking: Measure B struck down in Shasta court - Shasta Scout•COFEPRIS Approval Timelines: How Drug Classes Rank in 2026 - Mexico Business News•Time to protect physicians from moral injury in healthcare system - American Medical Association | AMA•What We’re Watching at COP31 - Center for Global Development•Tenzin Seldon Named to the 2026 TIME100 Most Influential Climate Leaders List, Pulse Fund Founder and Gross Domestic Regeneration Creator - Morningstar•Warner-Khawaja grenade threatens to tear Aussies apart - Nine.com.au•Atletico target Zubimendi move - Tuesday's gossip•Florida continues descent in CBS Sports' re-rank after Oklahoma loss - Gators Wire•Rocket Lab Q3: Revenue Beat, EPS Miss, Signs $515M Neutron Deals - Rocket Lab (NASDAQ:RKLB) - Benzinga•Earnings call transcript: Sohu posts Q3 2026 loss as revenue falls 26% - Investing.com India•US citizen shot by ICE officer near children’s bus stop sues government for $25m - The Guardian•Photos of Pope Leo XIV in Argentina in second leg of Latin American tour - Mankato Free Press•Päivi Räsänen warns hate speech laws are pushing Europe toward 'ideological totalitarianism' - Christian Post•Germany's Merz wants Ukraine aid pushed up EU summit agenda - Yahoo•Europe’s new fear about Trump - Politico•Skydance outlines its $6 billion in planned cost savings. Here's the breakdown•YouTube Squashes Feud With Billboard Charts•Jets disappointed ex-goalie Connor Hellebuyck sitting out - ESPN•Kansas' Melvin Council Jr. suffers broken foot, may be out until January - ESPN•Republican lawmaker moves to impeach US Defense Secretary Hegseth•Breaking: Measure B struck down in Shasta court - Shasta Scout•COFEPRIS Approval Timelines: How Drug Classes Rank in 2026 - Mexico Business News•Time to protect physicians from moral injury in healthcare system - American Medical Association | AMA•What We’re Watching at COP31 - Center for Global Development•Tenzin Seldon Named to the 2026 TIME100 Most Influential Climate Leaders List, Pulse Fund Founder and Gross Domestic Regeneration Creator - Morningstar•Warner-Khawaja grenade threatens to tear Aussies apart - Nine.com.au•Atletico target Zubimendi move - Tuesday's gossip•Florida continues descent in CBS Sports' re-rank after Oklahoma loss - Gators Wire•Rocket Lab Q3: Revenue Beat, EPS Miss, Signs $515M Neutron Deals - Rocket Lab (NASDAQ:RKLB) - Benzinga•Earnings call transcript: Sohu posts Q3 2026 loss as revenue falls 26% - Investing.com India•US citizen shot by ICE officer near children’s bus stop sues government for $25m - The Guardian•Photos of Pope Leo XIV in Argentina in second leg of Latin American tour - Mankato Free Press•Päivi Räsänen warns hate speech laws are pushing Europe toward 'ideological totalitarianism' - Christian Post•Germany's Merz wants Ukraine aid pushed up EU summit agenda - Yahoo•Europe’s new fear about Trump - Politico•Skydance outlines its $6 billion in planned cost savings. Here's the breakdown•YouTube Squashes Feud With Billboard Charts•Jets disappointed ex-goalie Connor Hellebuyck sitting out - ESPN•Kansas' Melvin Council Jr. suffers broken foot, may be out until January - ESPN•Republican lawmaker moves to impeach US Defense Secretary Hegseth
TheNewsPulse.pro
Home/clinical trials/diseases/drugs
clinical_trials

Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial

Confidence86·multiple reportsImportance88NP-EVT-20261109-2CACB49

(MedPage Today) -- ORLANDO -- Interim results from a prospective trial designed to evaluate safety of avacopan (Tavneos), the embattled drug for antineutrophil cytoplasmic antibody-associated vasculitis (AAV), indicated that the product could...

Read the original at the primary source
Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial
11/9/2026, 8:14:04 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse

Discussion

ChatsPulse · 0 threads

No discussion yet. Sign in and start the first thread —